Vibativ
Withdrawn
This medicine's authorisation has been withdrawn
telavancin
MedicineHumanWithdrawn
Portuguese is available via eTranslation, the European Commission's machine translation service.
Translate to Portuguese | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Vibativ has been withdrawn at the request of the marketing authorisation holder.
Product information
Latest procedure affecting product information:IAIN/0031
08/09/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Vibativ
- Active substance
- telavancin
- International non-proprietary name (INN) or common name
- telavancin
- Therapeutic area (MeSH)
- Pneumonia, Bacterial
- Cross Infection
- Anatomical therapeutic chemical (ATC) code
- J01XA03
Pharmacotherapeutic group
Antibacterials for systemic useTherapeutic indication
Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).
Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
News on Vibativ
This page was last updated on